Loading...
Docoh

Fuse Medical (FZMD)

Fuse Medical, Inc. is a distributor of medical devices. It provides a broad portfolio of orthopedic implants, including internal and external fixation products; upper and lower extremity plating; total joint reconstruction; soft tissue fixation and augmentation for sports medicine procedures; full spinal implants for trauma, degenerative disc disease, and deformity indications; human allografts, substitute bone materials, and tendons; and regenerative tissues and fluids to augment orthopedic surgeries and wound care. The company was founded in 1968 and is headquartered in Richardson, TX.

Company profile

Ticker
FZMD
Exchange
CEO
Christopher C. Reeg
Employees
Incorporated
Location
Fiscal year end
Former names
AMERICAN METALS SERVICE INC, GOLF ROUNDS COM INC
SEC CIK
Subsidiaries
CPM Medical Consultants, LLC ...
IRS number
591224913

FZMD stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 May 22
26 Jun 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 522.49K 522.49K 522.49K 522.49K 522.49K 522.49K
Cash burn (monthly) 10.23K 2.56K 117.81K 176.58K (no burn) 100.06K
Cash used (since last report) 29.37K 7.34K 338.13K 506.81K n/a 287.18K
Cash remaining 493.11K 515.14K 184.36K 15.67K n/a 235.31K
Runway (months of cash) 48.2 201.3 1.6 0.1 n/a 2.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
23 Dec 21 Brooks Mark W Common Stock Gift Dispose G Yes No 0 107,143 0 54,620,130
4 Nov 21 Brooks Mark W Grant Acquire A No No 0.68 73,530 50K 549,253
4 Nov 21 Reeg Christopher C Grant Acquire A No No 0.68 73,530 50K 549,253
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change

Financial report summary

?
Competition
StrykerOrthofix Medical
Risks
  • We may not be able to refinance, extend or repay our indebtedness owed to our secured lender, which would have a material adverse effect on our business, future operating results, and financial condition.
  • The COVID-19 outbreak may decrease demand for our products and disrupt our supply chain, and any decrease in demand or supply chain disruption resulting from COVID-19 would adversely affect our revenues and results of operations.
  • We have significant concentration in and dependence on a small number of customers.
  • We are exposed to risks of obsolete and slow-moving inventory which may adversely impact our cash flow and liquidity.
  • To grow revenues and profitability from certain products, we must expand our relationships with hospital systems, third-party distributors and independent sales representatives, whom we do not control.
  • Our revenue growth and profitability will depend in large part upon the effectiveness of our marketing strategies and investments.
  • Our revenues will depend on our customers’ continued receipt of adequate reimbursement from private insurers and government sponsored healthcare programs.
  • Consolidation in the healthcare industry could lead to demands for price concessions or to the exclusion of some suppliers from certain of our markets, which could have an adverse effect on our business, financial condition or results of operations.
  • Our operating earnings are dependent on certain significant suppliers.
  • Interruption of manufacturing operations could adversely affect our business.
  • Future business combinations or acquisitions may be difficult to integrate, which could cause us to shift our attention away from our primary business and its operations.
  • If the statutes and regulations in our industry change, our business could be adversely affected.
  • U.S. federal and state governmental regulation could restrict our ability to sell the products.
  • The FDA regulates the manufacturers and suppliers of the products that we sell, market, manufacture, and distribute, and regulatory compliance is costly and could contribute to delays in the availability of our products.
  • Future regulatory action remains uncertain.
  • If we fail to obtain, or experience significant delays in obtaining, FDA clearances or approvals for our future products or modifications to our products, our ability to commercially distribute and market our products could suffer.
  • Intellectual property litigation and infringement claims could cause us to incur significant expenses or prevent us from selling certain of our products.
  • We operate our business in regions subject to natural disasters and other catastrophic events, and any disruption to our business resulting from natural disasters would adversely affect our revenue and results of operations.
  • We cannot be certain that our internal controls over financial reporting and procedures will be sufficient in the future. This uncertainty could have a material adverse effect on our investors’ confidence in our reported financial information. There is no guarantee that our internal controls over financial reporting and procedures will not fail in the future.
  • We depend on the knowledge and skills of our executives and other key employees, and if we are unable to retain and motivate them or recruit additional qualified personnel, our business may suffer.
  • We may be adversely affected by product liability claims, unfavorable court decisions or legal settlements.
  • We do business with companies that are owned or controlled by our Chief Executive Officer and Chairman of the Board and President, which could create actual or potential conflicts of interest.
  • Some members of our executive team may dedicate inadequate time and attention to our Company.
  • General economic conditions may adversely affect demand for our products and services.
  • Because the market for our Common Stock is limited, persons who purchase our Common Stock may not be able to resell their shares at or above the purchase price they paid.
  • Our current executive team can exert significant influence over our Company and make decisions that are not in the best interests of all stockholders.
  • Under our charter documents and Delaware law, we could issue “blank check” preferred stock without stockholder approval, which would dilute our then current stockholders’ interests and impair such stockholders’ voting rights, discouraging a takeover that our stockholders may consider favorable.
  • If our Common Stock becomes subject to a “chill” or a “freeze” imposed by the Depository Trust Company (“DTC”) our stockholders’ ability to sell shares may be limited.
Management Discussion
  • ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. 
  • As used in this report on Form 10-Q, “we”, “us”, “our”, and the “Company” refer to Fuse Medical, Inc, a Delaware corporation. 
  • This discussion and analysis should be read in conjunction with the interim unaudited condensed consolidated financial statements of our Company and the related notes included in this report for the periods presented (our “Financial Statements”), the audited consolidated financial statements of our Company and the related notes thereto and the Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (our “2021 Annual Report”), filed with the Securities and Exchange Commission (the “SEC”) pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on March 31, 2022.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: advantage, Advisory, affirmative, alternate, cease, cellular, CNH, commercialization, commercialize, competitive, comply, constitute, deposit, description, disruption, dissolution, dissolved, entirety, Exhibit, fact, floating, foregoing, harsh, innovative, launch, lead, lender, maximum, mitigate, mitigated, multiple, negative, newly, Omicron, optimize, osseointegration, osteo, pledge, Prime, raw, regionally, repay, SAB, Scientific, skin, source, surged, synthetic, text, turnover, World
Removed: Carlo, certainty, contract, dependent, eligible, LOP, Monte, necessitated, order, Paycheck, reclassification, settlement, simulation, trailing, underlying